Innogen (02591.HK) announced a new pet-health division as it expands into developing innovative veterinary medicines. Drawing on its core expertise in metabolic diseases and its GLP-1 technology and commercialisation experience, the company will target common conditions in pets, including diabetes and obesity.
Image text and data — Pet health division and research infographic
The infographic announces Innogen's pet health division and entry into innovative veterinary medicines, applying its GLP-1 receptor agonist expertise in metabolic disease to research in pet diabetes and obesity.
Market text states that China's pet healthcare market exceeded RMB150 billion in 2024 and the pet-medicine market reached RMB28.6 billion, with 23.7% growth versus 5.2% for traditional veterinary medicines. A separate line-graph label reads +26.7%, without a defined measure or horizontal axis. The bar chart also lacks category labels or a numerical scale.
It describes increasing pet metabolic disease, diabetes and obesity as major conditions, and insufficient innovative-drug supply. The research panel lists clinical trials in progress and IND applications, with initial work on pet diabetes and obesity and adaptation of GLP-1RA technology for veterinary indications. Text attributed to Dr Qinghua Wang emphasizes medicines suited to pets' physiology. The lower-right corner states that the image was generated with AI.
Citing the 2025 China Pet Healthcare Industry White Paper, the announcement states that China's pet healthcare market exceeded RMB150 billion in 2024. Pet medicines accounted for RMB28.6 billion, up 23.7% year on year, compared with 5.2% growth in the traditional livestock and poultry medicines market. It describes rapid growth in pet healthcare and a rising incidence of metabolic diseases in pets, with diabetes and obesity becoming major health concerns, while a shortage of targeted, high-quality innovative medicines leaves substantial unmet needs.
Innogen will initially focus on pet diabetes and obesity, adapting and optimising its core GLP-1 receptor agonist technology for veterinary indications while considering safety, efficacy and ease of administration. The announcement states that early research has begun and clinical trials are under way. The company plans to use its established capabilities in clinical trials, quality control and commercialisation to accelerate development and market introduction.
Founder, Chairman and Chief Executive Officer Dr Qinghua Wang said pet health is an important part of family health. Years of work in metabolic diseases have highlighted pathological mechanisms shared by humans and pets. He expressed confidence that Innogen's GLP-1 receptor agonist expertise would support medicines better suited to pets' physiology, address gaps in the market and extend the benefits of innovative medical technology to more lives.